Role of EZH2 polymorphisms in Esophageal Squamous Cell carcinoma risk in Han Chinese population

International Journal of Molecular Sciences

Volumn 15, Issue 7, 2014, Pages 12688-12697

  Ma, Zhen Bin ^a   Guo, Guang Hong ^a   Niu, Qiong ^a   Shi, Ning ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Allele; Esophageal squamous cell carcinoma; EZH2; Polymorphism

Indexed keywords

GENOMIC DNA; POLYCOMB GROUP PROTEIN; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADULT; AGED; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; DNA SEQUENCE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EZH2 GENE; FAMILY HISTORY; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION RATE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TUMOR VOLUME; CASE CONTROL STUDY; CHINA; ESOPHAGUS TUMOR; GENETICS; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84904498034     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms150712688     Document Type: Article

References (33)

1. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Suntharalingam, M. Definitive chemoradiation in the management of locally advanced esophageal cancer. Semin. Radiat. Oncol. 2007, 17, 22-28.
3. Rohatgi, P. R.; Swisher, S. G.; Correa, A. M.; Wu, T. T.; Liao, Z.; Komaki, R.; Walsh, G.; Vaporciyan, A.; Lynch, P. M.; Rice, D. C.; et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer 2005, 104, 1349-1355.
4. Di Fiore, F.; Lecleire, S.; Rigal, O.; Galais, M. P.; Ben Soussan, E.; David, I.; Paillot, B.; Jacob, J. H.; Michel, P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J. Gastroenterol. 2006, 12, 4185-4190.
5. Hu, J.; Nyren, O.; Wolk, A.; Bergstrom, R.; Yuen, J.; Adami, H. O.; Guo, L.; Li, H.; Huang, G.; Xu, X.; et al. Risk factors for oesophageal cancer in northeast China. Int. J. Cancer 1994, 57, 38-46.
6. Zhou, L.; Zhang, X.; Li, Z.; Zhou, C.; Li, M.; Tang, X.; Lu, C.; Li, H.; Yuan, Q.; Yang, M. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLoS One 2013, 8, e64331.
7. Zhu, M. L.; Shi, T. Y.; Hu, H. C.; He, J.; Wang, M.; Jin, L.; Yang, Y. J.; Wang, J. C.; Sun, M. H.; Chen, H.; et al. Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations. PLoS One 2012, 7, e41500.
8. Mathews, L. A.; Crea, F.; Farrar, W. L. Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation 2009, 78, 1-17.
9. Simon, J. A.; Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647, 21-29.
10. Tonini, T.; D'Andrilli, G.; Fucito, A.; Gaspa, L.; Bagella, L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J. Cell. Physiol. 2008, 214, 295-300.
11. Cardoso, C.; Mignon, C.; Hetet, G.; Grandchamps, B.; Fontes, M.; Colleaux, L. The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur. J. Hum. Genet. 2000, 8, 174-180.
12. Van Kemenade, F. J.; Raaphorst, F. M.; Blokzijl, T.; Fieret, E.; Hamer, K. M.; Satijn, D. P.; Otte, A. P.; Meijer, C. J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001, 97, 3896-3901.
13. Matsukawa, Y.; Semba, S.; Kato, H.; Ito, A.; Yanagihara, K.; Yokozaki, H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci. 2006, 97, 484-491.
14. Mimori, K.; Ogawa, K.; Okamoto, M.; Sudo, T.; Inoue, H.; Mori, M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol. 2005, 31, 376-380.
15. Collett, K.; Eide, G. E.; Arnes, J.; Stefansson, I. M.; Eide, J.; Braaten, A.; Aas, T.; Otte, A. P.; Akslen, L. A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12, 1168-1174.
16. Bachmann, I. M.; Halvorsen, O. J.; Collett, K.; Stefansson, I. M.; Straume, O.; Haukaas, S. A.; Salvesen, H. B.; Otte, A. P.; Akslen, L. A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24, 268-273.
17. Kidani, K.; Osaki, M.; Tamura, T.; Yamaga, K.; Shomori, K.; Ryoke, K.; Ito, H. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 2009, 45, 39-46.
18. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G.; Otte, A. P.; et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624-629.
19. He, L. R.; Liu, M. Z.; Li, B. K.; Jia, W. H.; Zhang, Y.; Liao, Y. J.; Chen, Y. C.; Zhang, L. J.; Guan, X. Y.; Zeng, Y. X. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer 2010, 127, 138-147.
20. Wang, J.; Ma, Z. B.; Li, K.; Guo, G. H. Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population. Med. Oncol. 2014, 31, 874.
21. Valk-Lingbeek, M. E.; Bruggeman, S. W.; van Lohuizen, M. Stem cells and cancer; the polycomb connection. Cell 2004, 118, 409-418.
22. Lund, A. H.; van Lohuizen, M. Polycomb complexes and silencing mechanisms. Curr. Opin. Cell Biol. 2004, 16, 239-246.
23. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S. A.; Ghosh, D.; Sewalt, R. G.; Otte, A. P.; Hayes, D. F.; et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 2003, 100, 11606-11611.
24. Jacobs, J. J.; Kieboom, K.; Marino, S.; DePinho, R. A.; van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397, 164-168.
25. Sasaki, M.; Yamaguchi, J.; Itatsu, K.; Ikeda, H.; Nakanuma, Y. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 2008, 215, 175-183.
26. Crea, F.; Fornaro, L.; Paolicchi, E.; Masi, G.; Frumento, P.; Loupakis, F.; Salvatore, L.; Cremolini, C.; Schirripa, M.; Graziano, F. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 2012, 23, 1207-1213.
27. Yoon, K. A.; Gil, H. J.; Han, J.; Park, J.; Lee, J. S. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J. Thorac. Oncol. 2010, 5, 10-16.
28. Shen, Z.; Chen, L.; Hao, F.; Wang, G.; Fan, P.; Liu, Y. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J. Cell. Mol. Med. 2010, 14, 226-241.
29. Zhang, W.; Winder, T.; Ning, Y.; Pohl, A.; Yang, D.; Kahn, M.; Lurje, G.; Labonte, M.; Wilson, P.; Gordon, M. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol. 2011, 22, 104-109.
30. Lipkin, S. M.; Chao, E. C.; Moreno, V.; Rozek, L. S.; Rennert, H.; Pinchev, M.; Dizon, D.; Rennert, G.; Kopelovich, L.; Gruber, S. B. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev. Res. 2010, 3, 597-603.
31. Fornaro, L.; Crea, F.; Masi, G.; Paolicchi, E.; Loupakis, F.; Graziano, F.; Salvatore, L.; Ronzoni, M.; Ricci, V.; Cremolini, C.; et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: Another piece to the puzzle. Ann. Oncol. 2012, 23, 1370-1371.
32. Edge, S. B. American Joint Committee on Cancer. In AJCC Cancer Staging Manual, 7th ed.; Springer: New York, NY, USA, 2010; p. 648.
33. Nazir, M.; Kayani, M. R.; Malik, F. A.; Masood, N.; Kayani, M. A. Lack of germ line changes in KISS1 and KAI1 genes in sporadic head and neck cancer patients of Pakistani origin. Asian Pac. J. Cancer Prev. 2011, 12, 2767-2771.